IN2014KN01026A - - Google Patents

Info

Publication number
IN2014KN01026A
IN2014KN01026A IN1026KON2014A IN2014KN01026A IN 2014KN01026 A IN2014KN01026 A IN 2014KN01026A IN 1026KON2014 A IN1026KON2014 A IN 1026KON2014A IN 2014KN01026 A IN2014KN01026 A IN 2014KN01026A
Authority
IN
India
Prior art keywords
formation
inducing
cartilage
capability
bone
Prior art date
Application number
Inventor
Frank Plöger
Florian Wagner
Original Assignee
Bioph Biotech Entw Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioph Biotech Entw Pharm Gmbh filed Critical Bioph Biotech Entw Pharm Gmbh
Publication of IN2014KN01026A publication Critical patent/IN2014KN01026A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention is directed to GDF 5 related proteins having an improved capability of inducing cartilage formation and a reduced capability of inducing bone formation. The novel proteins are particularly useful in the treatment of cartilage defects wherein the formation of bone tissue is undesirable.
IN1026KON2014 2011-12-05 2012-12-05 IN2014KN01026A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11191973.4A EP2602264A1 (en) 2011-12-05 2011-12-05 GDF-5 mutant for inducing cartilage formation
PCT/EP2012/074549 WO2013083649A1 (en) 2011-12-05 2012-12-05 Gdf-5 mutant for inducing cartilage formation

Publications (1)

Publication Number Publication Date
IN2014KN01026A true IN2014KN01026A (en) 2015-10-09

Family

ID=47278877

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1026KON2014 IN2014KN01026A (en) 2011-12-05 2012-12-05

Country Status (23)

Country Link
US (1) US9718867B2 (en)
EP (3) EP2602264A1 (en)
JP (1) JP6185926B2 (en)
KR (1) KR102067724B1 (en)
CN (1) CN104039820B (en)
AU (1) AU2012347305B2 (en)
BR (1) BR112014013122A2 (en)
CA (1) CA2856458C (en)
DK (2) DK2788374T3 (en)
EA (1) EA028554B1 (en)
ES (2) ES2630853T3 (en)
HK (1) HK1198768A1 (en)
HR (2) HRP20170205T1 (en)
HU (2) HUE042191T2 (en)
IN (1) IN2014KN01026A (en)
LT (2) LT3168230T (en)
MX (1) MX351809B (en)
PL (2) PL2788374T3 (en)
PT (2) PT3168230T (en)
RS (2) RS55686B1 (en)
SI (2) SI2788374T1 (en)
TR (1) TR201901263T4 (en)
WO (1) WO2013083649A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101639269B1 (en) 2015-12-02 2016-07-13 주식회사 셀루메드 Method for improving alkaline phosphatase assay
EP4076502A1 (en) 2019-12-18 2022-10-26 Merck Patent GmbH Use of the gdf-5 mutant for the treatment of pain and cartilage destruction
CN111701075A (en) * 2020-06-24 2020-09-25 亘元(天津)生物医药科技有限公司 Cartilage repair material, cartilage reconstruction biological scaffold and preparation method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1439190A1 (en) 1993-01-12 2004-07-21 The Johns Hopkins University School Of Medicine Growth differentiation factor-5
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
BR9608019A (en) 1995-04-19 1999-11-30 Hoechst Japan A new protein and a process for preparing it '
JPH0931098A (en) 1995-07-24 1997-02-04 Hoechst Japan Ltd New protein hmw human mp52
ZA966489B (en) 1995-08-03 1997-02-26 Bioph Biotech Entw Pharm Gmbh New protein human MP52 Arg.
DE19647853A1 (en) 1996-11-19 1998-05-20 Bioph Biotech Entw Pharm Gmbh Compounds with improved cartilage and / or bone inducing activity
EP1074620A1 (en) 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
JPH11335398A (en) 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk New monomeric protein having bone-inducing activity and preventive/therapeutic agent for chondropathy/ osteopathy consisting thereof
JP2000119192A (en) 1998-10-09 2000-04-25 Aventis Pharma Ltd Mature type protein having antagonistic activity for bone morphogenetic protein
DE10026713A1 (en) 2000-05-30 2001-12-06 Walter Sebald Mutein a chain of a protein from the superfamily of the growth factor TGF-beta
KR100530299B1 (en) * 2003-08-11 2005-11-22 산도즈 게엠베하 Cephalosporin c acylase mutant and method for preparing 7-aca using same
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
EP1698691A1 (en) * 2005-03-04 2006-09-06 Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH Growth factor mutants with improved biological activity
EP1721909A1 (en) 2005-05-10 2006-11-15 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Growth factor mutants with altered biological attributes
JP2007054013A (en) * 2005-08-26 2007-03-08 Research Institute Of Innovative Technology For The Earth Thermostable l-threonine aldolase and gene encoding the same
AU2006314713B2 (en) * 2005-11-18 2011-10-06 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh High activity growth factor mutants
CN103641916A (en) 2006-03-27 2014-03-19 医学免疫有限公司 Binding member for gm-csf receptor
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
CN103079585B (en) 2010-08-20 2015-09-30 惠氏有限责任公司 Through the BMP of design

Also Published As

Publication number Publication date
HRP20190160T8 (en) 2020-02-07
TR201901263T4 (en) 2019-02-21
DK2788374T3 (en) 2017-04-10
EP3168230A1 (en) 2017-05-17
WO2013083649A1 (en) 2013-06-13
CA2856458C (en) 2024-03-12
AU2012347305B2 (en) 2016-11-03
ES2630853T3 (en) 2017-08-24
AU2012347305A1 (en) 2014-06-26
EP2788374A1 (en) 2014-10-15
PT3168230T (en) 2019-01-30
HUE033025T2 (en) 2017-11-28
PL3168230T3 (en) 2019-06-28
EP2788374B1 (en) 2017-01-04
LT3168230T (en) 2019-03-12
EA028554B1 (en) 2017-11-30
PL2788374T3 (en) 2017-08-31
JP6185926B2 (en) 2017-08-23
DK3168230T3 (en) 2019-01-14
US20140369978A1 (en) 2014-12-18
EP3168230B1 (en) 2018-12-05
KR102067724B1 (en) 2020-01-17
RS55686B1 (en) 2017-07-31
CA2856458A1 (en) 2013-06-13
JP2015504649A (en) 2015-02-16
EP2602264A1 (en) 2013-06-12
EA201491119A1 (en) 2014-12-30
SI2788374T1 (en) 2017-04-26
US9718867B2 (en) 2017-08-01
PT2788374T (en) 2017-02-15
CN104039820B (en) 2018-01-09
HRP20190160T1 (en) 2019-03-22
HK1198768A1 (en) 2015-06-05
LT2788374T (en) 2017-02-10
SI3168230T1 (en) 2019-03-29
HRP20170205T1 (en) 2017-06-16
MX2014006465A (en) 2015-03-20
MX351809B (en) 2017-10-30
HUE042191T2 (en) 2019-06-28
KR20140100969A (en) 2014-08-18
ES2708675T3 (en) 2019-04-10
RS58253B1 (en) 2019-03-29
BR112014013122A2 (en) 2020-10-27
CN104039820A (en) 2014-09-10

Similar Documents

Publication Publication Date Title
IN2014DN10386A (en)
EA201390803A1 (en) Bromodomain inhibitors and their use
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2464724A4 (en) Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX343640B (en) Osteogenesis promoter.
BR112014009418A2 (en) peptidomimetic macrocycles
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
ZA201403596B (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
HRP20150117T1 (en) Collagenase g and collagenase h compositions for the treatment of diseases involving alterations of collagen
EP2515926A4 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
SMT201600147B (en) METHODS TO IMPROVE THE EXPRESSION OF RECOMBINANT PROTEINS
PH12014501200B1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA201170294A1 (en) METHODS OF TREATMENT OF REPERFUSION DAMAGE
MY163257A (en) Humanised anti-cd52 antibodies
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
MX2013002121A (en) Substituted quinoline-3-carboxamides as kcnq2/3 modulators.
IN2014DN00254A (en)
MX347541B (en) Sialic acid analogs.
IN2014KN01026A (en)
EP2637682A4 (en) Methods and compositions comprising cyclic analogues of histatin 5 for treating wounds
MX342239B (en) Compositions and methods for the diagnosis and treatment of tumor.
EA201390759A1 (en) BENZOXASEINS AS mTOR INHIBITORS AND METHODS OF THEIR USE AND MANUFACTURE
UY34485A (en) INHIBITORS OF THE PEPTIDE DESFORMILASA